Nitro-Dur

prophylaxis of Angina pectoris, Congestive Heart Failure, Chest Pain + 10 more

Treatment

15 Active Studies for Nitro-Dur

What is Nitro-Dur

Nitroglycerin

The Generic name of this drug

Treatment Summary

Nitroglycerin is a drug used to relax the blood vessels and reduce chest pain and high blood pressure. It was approved in 2000 and is made by Pfizer in different forms, including a spray, tablets placed under the tongue, intravenous injections, extended-release tablets, and a patch applied to the skin. Not many people know that nitroglycerin can also be used as an ointment to relieve the pain of anal fissures. The rectal ointment form was approved by the FDA in 1955.

Nitroglycerin

is the brand name

image of different drug pills on a surface

Nitro-Dur Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nitroglycerin

Nitroglycerin

1981

182

Effectiveness

How Nitro-Dur Affects Patients

Nitroglycerin helps to relax the blood vessels, increasing blood flow to the heart, reducing the pressure in the arteries and veins, and decreasing the strain on the heart. Over time, taking nitroglycerin can make it less effective as it may reduce the body's response to it. This can be caused by an enzyme (aldehyde dehydrogenase) being blocked, which can also lead to pro-oxidant effects, a decrease in the health of the cells lining the inside of blood vessels, and increased sensitivity to other drugs that cause narrowing of the blood vessels.

How Nitro-Dur works in the body

Nitroglycerin works by releasing nitric oxide in smooth muscle cells. Nitric oxide then activates an enzyme which produces a chemical called cGMP. The cGMP causes the muscle cells to relax, allowing more blood to flow and decreasing the pressure in the veins and arteries. This relaxation of the muscle cells also helps reduce the pressure in the heart, which is important for people with heart conditions. Nitric oxide may also target a specific receptor to help the body get rid of extra sodium, which helps reduce blood pressure.

When to interrupt dosage

The measure of Nitro-Dur is dependent upon the recognized illness, like Coronary Artery Spasm, induction of Uterine relaxation and Anal Fissure. The dosage fluctuates as per the technique of delivery (e.g. Tablet or Tablet - Oral) featured in the table beneath.

Condition

Dosage

Administration

Chest Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Coronary Disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Anal Fissure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

induction of Intraoperative Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

insufficient response to beta-blockers

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

nitroglycerin

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Angina Pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Congestive Heart Failure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypertensive disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

prophylaxis of Angina pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Myocardial Infarction

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Warnings

Nitro-Dur has eleven contraindications and should not be used in the presence of any of the conditions enumerated in the following table.

Nitro-Dur Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nitroglycerin may interact with Pulse Frequency

Cardiac Tamponade

Do Not Combine

Pulse Frequency

Do Not Combine

Hypovolemic Shock

Do Not Combine

Anemia

Do Not Combine

Pick Disease of Heart

Do Not Combine

Pulse Frequency

Do Not Combine

Acute Circulatory Failure

Do Not Combine

Intracranial Hypertension

Do Not Combine

Cardiomyopathy, Restrictive

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Nitro-Dur.

Common Nitro-Dur Drug Interactions

Drug Name

Risk Level

Description

Amediplase

Major

The therapeutic efficacy of Amediplase can be decreased when used in combination with Nitroglycerin.

Amifostine

Major

Nitroglycerin may increase the hypotensive activities of Amifostine.

Desmoteplase

Major

The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Nitroglycerin.

Reteplase

Major

The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.

Riociguat

Major

Nitroglycerin may increase the hypotensive activities of Riociguat.

Nitro-Dur Toxicity & Overdose Risk

An overdose of nitroglycerin can cause low blood pressure, a headache that won't go away, dizziness, heart palpitations, blurred vision, red and sweaty skin that later turns pale and blue, nausea, diarrhea (possibly with blood), fainting (especially when standing up), abnormally high levels of methemoglobin in the blood (causing cyanosis and loss of appetite), shallow breathing, and a slow pulse. Severe cases may lead to confusion, fever, paralysis, seizures, and even death due to circulatory collapse. Methemoglobinemia is a rare side effect which can occur at normal

image of a doctor in a lab doing drug, clinical research

Nitro-Dur Novel Uses: Which Conditions Have a Clinical Trial Featuring Nitro-Dur?

At present, 38 active investigations are looking into the efficacy of Nitro-Dur in providing Gastroesophageal variceal hemorrhage prophylaxis, Hypotension and Congestive Heart Failure alleviation.

Condition

Clinical Trials

Trial Phases

Coronary Disease

1 Actively Recruiting

Not Applicable

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pain

0 Actively Recruiting

prophylaxis of Angina pectoris

0 Actively Recruiting

Hypertensive disease

0 Actively Recruiting

induction of Intraoperative Hypotension

0 Actively Recruiting

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Anal Fissure

1 Actively Recruiting

Phase 1

Hypotension

0 Actively Recruiting

insufficient response to beta-blockers

0 Actively Recruiting

Angina Pectoris

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

nitroglycerin

0 Actively Recruiting

Nitro-Dur Reviews: What are patients saying about Nitro-Dur?

5

Patient Review

4/30/2016

Nitro-Dur for Heart Attack

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nitro-dur

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you leave Nitro-Dur on?

"Apply one patch on an adult once a day in the morning, and leave the patch in place for a total of 12 to 14 hours."

Answered by AI

Is Nitro-Dur transdermal?

"The organic nitrates are vasodilators, which means they widen blood vessels. The NITRO-DUR Transdermal Infusion System is a flat unit that releases a continuous, controlled amount of nitroglycerin through the skin."

Answered by AI

What is Nitro-Dur used for?

"This drug works by relaxing and widening the blood vessels so that blood can flow more easily to the heart.

This medication is used to prevent chest pain (angina) in people with a certain heart condition (coronary artery disease) by relaxing and widening the blood vessels so that blood can flow more easily to the heart."

Answered by AI

What is the generic name for Nitro-Dur?

"This medicine is a patch used to treat or prevent attacks of chest pain (angina).

The medicine is a patch that is used to treat or prevent episodes of chest pain that are caused by angina."

Answered by AI

Clinical Trials for Nitro-Dur

Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA

The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.

Recruiting
Has No Placebo

Ronald Reagan UCLA Medical Center

Have you considered Nitro-Dur clinical trials?

We made a collection of clinical trials featuring Nitro-Dur, we think they might fit your search criteria.
Go to Trials
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Image of Brigham and Women's Hospital in Boston, United States.

Care Transitions App for Multiple Chronic Conditions

18+
All Sexes
Boston, MA

The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Lipika Samal, MD, MPH

Image of Saint Luke's Hospital of Kansas City in Kansas City, United States.

Remote Patient Monitoring for Heart Failure

18 - 80
All Sexes
Kansas City, KS

Previous research has investigated the use of remote patient monitoring in various clinical contexts, however there has not been a clinical trial examining use of the VitalCare platform for ambulatory management of heart failure. This trial will serve as a pilot study examining the feasibility of use of the VitalCare platform for ambulatory heart failure management and examine the effect of remote patient monitoring on patient engagement. To the investigators' knowledge, this will be the first study examining the effect of remote patient monitoring with the VitalCare platform on heart failure clinical outcomes, such as hospitalization for heart failure exacerbations and emergency room visits for heart failure.

Waitlist Available
Has No Placebo

Saint Luke's Hospital of Kansas City (+3 Sites)

Have you considered Nitro-Dur clinical trials?

We made a collection of clinical trials featuring Nitro-Dur, we think they might fit your search criteria.
Go to Trials
Image of Columbia University Medical Center/ NewYork Presbyterian Hospital in New York, United States.

CTO PCI for Chronic Total Occlusions

18+
All Sexes
New York, NY

Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success rates at subsequent attempts. It has never been investigated whether a planned investment procedure, with an intention that both the initial and staged completion PCI are of shorter duration, could improve safety and efficacy. The investigators hypothesize that 1. A planned investment procedure in the treatment of CTOs will be associated with improved patient safety 2. A planned investment procedure will be associated with improved cumulative procedure success rates 3. A planned two stage procedure will be associated with improved patient experience

Waitlist Available
Has No Placebo

Columbia University Medical Center/ NewYork Presbyterian Hospital

Margaret B Mcentegart, PhD

Have you considered Nitro-Dur clinical trials?

We made a collection of clinical trials featuring Nitro-Dur, we think they might fit your search criteria.
Go to Trials